Results 41 to 50 of about 10,751 (182)

Table S6 from Phase I Study of the Efficacy and Safety of Ramucirumab in Combination with Osimertinib in Advanced T790M-positive EGFR-mutant Non–small Cell Lung Cancer

, 2021
Ramucirumab Serum Concentrations After Ramucirumab ...
Huzhang Mao (5436653), Rebecca R. Hozak (11197949), Ling Gao (429702), David Planchard (5843483), Keunchil Park (15028428), James Chih-Hsin Yang (7428557), Bo H. Chao (15028434), Helena A. Yu (7830836), Ki Hyeong Lee (15028425), Pilar Garrido (15013290), Sameera R. Wijayawardana (9561830), Joo-Hang Kim (710974), Dae Ho Lee (15028431), Luis G. Paz-Ares (15013287)   +13 more
core   +1 more source

Endothelium capture‐based liver segment imaging using vascular endothelial growth factor receptor 2 in preclinical ex vivo models

BJS Open, 2020
Background Near‐infrared (NIR) imaging of liver segments provides substantial information for surgeons performing liver resection. It was hypothesized that ramucirumab, an endothelium‐specific antibody approved by the Food and Drug Administration, could ...
D. Kyuno, B. Qian, W. Groß, M. Schäfer, E. Ryschich   +4 more
doaj   +1 more source

Ramucirumab [PDF]

Reactions Weekly, 2020
  +8 more sources

Age does not influence efficacy of ramucirumab in advanced gastric cancer: Subgroup analyses of REGARD and RAINBOW [PDF]

, 2018
BACKGROUND AND AIM: REGARD and RAINBOW were global, phase 3, randomized, double-blind trials of second-line ramucirumab for metastatic gastric or gastroesophageal junction adenocarcinoma.
Yanzhi Hsu, Eric Van Cutsem, Charles Fuchs, Cheng, R, Josep Tabernero, Chao, Y, Muro, K, Shimada, Y, dos Santos, LV, Tabernero, J, Bodoky, G, Chanchal Goswami, Michael Emig, Rebecca Cheng, Hsu, Y, Jae Yong Cho, Yee Chao, Mauro Orlando, Cho, JY, Ian Chau, Gyorgy Bodoky, Stefano Cascinu, Eldar Topuzov, Orlando, M, Van Cutsem, E, Goswami, C, Topuzov, E, Kei Muro, Lucas V dos Santos, John Zalcberg, Emig, M, Fuchs, C, Chau, I, Cascinu, S, Yasuhiro Shimada, Zalcberg, J, Chao Y., Fuchs C., Orlando M., Topuzov E., Goswami C., Cho J. Y., dos Santos L. V., Bodoky G., Chau I., Hsu Y., Zalcberg J., Van Cutsem E., Muro K., Shimada Y., Cheng R., Tabernero J., Cascinu S., Emig M.   +53 more
core   +1 more source

Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma

Cancer Medicine, 2021
Background Preclinical data suggest that vascular endothelial growth factor (VEGF) and transforming growth factor (TGF)‐β signaling interact to stimulate angiogenesis and suppress antitumor immune responses. Thus, combined inhibition of both pathways may
James J. Harding, Richard K. Do, Amin Yaqubie, Ann Cleverly, Yumin Zhao, Ivelina Gueorguieva, Michael Lahn, Karim A. Benhadji, Robin K. Kelley, Ghassan K. Abou‐Alfa   +9 more
doaj   +1 more source

Preclinical assessment of intravitreal ramucirumab: in vitro and in vivo safety profile

International Journal of Retina and Vitreous, 2020
Background Anti-angiogenic drugs remain the mainstay therapy for several vascular retinal pathologies. The repurposing of approved anti-angiogenic drugs for use in ophthalmology can increase therapeutic options and reduce costs. The purpose of this study
Jarbas Emílio de Moraes Neto, Felipe Pereira, Raquel Leão Neves, Nilana Meza Tenório de Barros, Cristiane Damas Gil, Arthur Gustavo Fernandes, Sung Eun Song Watanabe, Carsten Helmut Meyer, Michel Eid Farah, Eduardo Buchele Rodrigues   +9 more
doaj   +1 more source

Targeting the CD47–SIRPα phagocytic checkpoint in cancer: Biology, translational opportunities, and next‐generation therapeutic strategies

Smart Molecules, EarlyView.
The CD47–SIRPα axis has emerged as a critical innate immune checkpoint that suppresses macrophage‐mediated phagocytosis through a canonical “don't eat me” signal and enables tumor immune evasion. We comprehensively summarize the structural and biological features of CD47 and the molecular mechanisms underlying CD47‐mediated regulation of phagocytosis ...
Ruimei Zhou, Lingjie Jing, Jianping Zhang, Cheng Guo, Quanjun Yang   +4 more
wiley   +1 more source

REAL-LIFE CLINICAL UTILITY OF RAMUCIRUMAB FOR THE TREATMENT OF PATIENTS WITH DISSEMINATED GASTRIC ADENOCARCINOMA: PRELIMINARY REVIEW OF THE EXPERIENCE OF BLOKHIN RUSSIAN CANCER RESEARCH CENTRE

Медицинский совет, 2017
Angiogenesis   has  become  an  important  target  in  the  treatment  of  solid  tumors  and  anti-angiogenic   agents   are a  promising  approach  to  cancer  therapy.
N. S. Besova, T. A. Titova, V. A. Gorbunova, O. O. Gordeeva, A. A. Tryakin, A. V. Snegovoy, R. Yu. Nasyrova, A. A. Rumyantsev, E. A. Voroshilova, E. V. Artamonova   +9 more
doaj   +1 more source

Case report of partial response on second line with Ramucirumab and FOLFIRI in treatment of 74 year old male with metastatic HER2-negative gastric adenocarcinoma

Медицинский совет, 2021
According to the data of the world statistics, gastric cancer (GC) occupies the 5th place by morbidity and the 3rd one by mortality among malignant neoplasms.
N. S. Besova, T. A. Titova, A. E. Kalinin, V. A. Shalenkov, I. S. Stilidi   +4 more
doaj   +1 more source

MEN1 Deficiency Drives Lung Cancer Progression via Activation of MMP10‐Mediated Angiogenesis

Cancer Science, EarlyView.
MEN1 deficiency promotes JunD‐mediated upregulation of MMP10 expression, which cleaves pro‐HB‐EGF and activates endothelial EGFR. This triggers the PI3K/Akt and MEK/ERK signaling pathways, thereby driving angiogenesis and tumor progression. MMP10 inhibitor treatment blocks this cleavage, suppresses EGFR signaling, and thereby delays malignant ...
Chengyu Wei, Xiangyu Liu, Shimin Hu, Xiaodie Shen, Yingli Liu, Xinxin Qin, Ye Zhou, Jianqi Zheng, Bingke Tian, Jingfang Hong, Yongxia Song, Di Wang, Linlin Peng, Jinxia Ding, Fang Wang, Hui Zhang, Shihao Zhang, Huan Qiu   +17 more
wiley   +1 more source